Plus Therapeutics Inc expected to post a loss of $1.07 a share - Earnings Preview

Cerenome

23/02/2024 19:19

* Plus Therapeutics Inc  PSTV.OQ   PSTV.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2023
    * The Austin Texas-based  company is expected to report a
604.0% increase in revenue to $1.063 million from $151 thousand
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data. (Majority is on Total Revenue Basis)
    * ​LSEG's mean analyst estimate for Plus Therapeutics Inc is
for a
loss of $1.07 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Plus
Therapeutics
Inc is $21.00​, above​ its last closing price of $1.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.02       -1.12      -1.00     Beat    10.9
 Jun. 30 2023  -1.93       -1.91      -0.59     Beat    69.2
 Mar. 31 2023  -1.91       -1.90      -2.10     Missed  -10.5​
 Dec. 31 2022  -1.50       -1.80      -3.30     Missed  -83.3
 ​​Sep.        -3.02       -3.04      -2.85     Beat    6.2
 30 2022                                                
 Jun. 30 2022  -3.57       -3.25      -3.60     Missed  -10.8​
 Mar. 31 2022  -2.72       -2.70      -2.85     Missed  -5.6
 Dec. 31 2021  -4.14       -4.05      -4.05     Met     0
 This summary was machine generated February 23 at 19:19 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)